UBS analyst Ashwani Verma upgraded Alkermes (ALKS) to Buy from Neutral with a price target of $42, up from $33. The firm says its recent physician survey drives confidence that ALKS-2680 is well positioned to potentially establish itself as an attractive treatment option in narcolepsy idiopathic hypersomnia. The shares re current levels are pricing in $1.2B in 2030 sales versus UBS’s base case of $1.8B, the analyst tells investors in a research note. The firm believes data readouts in the second half of 2025 from Alkermes and peers can drive excitement behind the orexin class.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes presenting new research related to ALKS 2680 at SLEEP 2025
- Alkermes initiated with a Buy at Needham
- Alkermes Poised for Growth with Promising ALKS 2680 and Strategic Pipeline Expansion
- Alkermes Shareholders Approve Amendments at Annual Meeting
- Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright